SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers
hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases. The …

The vast interindividual clinical variability observed in any microbial infection—ranging from
silent infection to lethal disease—is increasingly being explained by human genetic and …

INTRODUCTION Interindividual clinical variability is vast in humans infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to rapid …

Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma
diluted 1:10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 …

Type I interferons (IFNs) have broad and potent antiviral activity. We review the interplay
between type I IFNs and SARS-CoV-2. Human cells infected with SARS-CoV-2 in vitro produce …

The relation between infections and autoimmune diseases has been extensively investigated.
Multiple studies suggest a causal relation between these two entities with molecular …

INTRODUCTION Clinical outcomes of human severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus disease 2019 (…

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing …

Disclosures: PD Burbelo reported US Patent no. 10,564,152 issued. JC Casanova reported
a patent to 63/055,155 pending and a patent to 63/141,669 pending. No other disclosures …

IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2
infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3–…